What “flashback” actually means clinically

The word flashback gets used loosely. In a clinical PTSD context, it has a specific meaning: an involuntary, intrusive re-experiencing of a traumatic event, often with the felt sense that it is happening right now. The DSM-5 lists flashbacks as a hallmark intrusion symptom of PTSD, alongside nightmares and unbidden memories. They are unwanted. They hijack the present. They can dissolve the boundary between past and present in ways that are genuinely frightening.

That is not the same thing as a vivid memory or an emotional moment. The defining features are loss of present-moment awareness, autonomic activation, and the sense of reliving rather than remembering. People who live with PTSD know the difference, and they are right to ask whether a treatment that alters perception could provoke that kind of episode.

The honest answer requires distinguishing two different experiences that can both look strange from the outside: the dissociation produced by therapeutic ketamine, and a true PTSD flashback. They are not the same.

Dissociation vs. flashback — they are not the same thing

Ketamine produces a state of dissociation. At sub-anesthetic doses, this typically feels dreamlike, floaty, and observational—patients often describe a sense of distance from the body, mild visual softening, and a quieter inner voice. It is time-limited, follows a predictable curve, and resolves within roughly 15 to 30 minutes after the infusion ends. Most patients describe it as neutral or pleasant. Some describe it as profound. A small minority find it unsettling but contained.

A PTSD flashback is different. It is an involuntary, present-tense reliving of trauma. It carries autonomic load—racing heart, sweating, sense of threat—and a felt loss of agency. It can be triggered by sensory cues that resemble the original event. The person inside the flashback usually does not know it is a flashback while it is happening.

These are different mechanisms. Dissociation under ketamine reflects glutamate-driven changes in cortical communication. A flashback reflects a pattern in the trauma memory network being activated. One is induced by a known pharmacology with a known offset. The other is unpredictable and rooted in trauma physiology.

This distinction matters because what some patients report as “a flashback during ketamine” is, on careful interview, almost always either dissociative content with emotional weight or a vivid memory that surfaced and could be processed. True clinical flashbacks during well-conducted medical infusions are rare in the published literature.

What the research says about ketamine and PTSD

If ketamine routinely caused or worsened flashbacks, the trials studying it for PTSD would have shown that signal clearly. They have shown the opposite.

A landmark 2014 randomized controlled trial by Feder and colleagues, published in JAMA Psychiatry, compared a single IV ketamine infusion against a midazolam active control in patients with chronic PTSD. The ketamine group showed rapid and significant reduction in PTSD symptoms within 24 hours. Adverse effects included expected transient dissociative symptoms, but the study did not report induction of new flashbacks or worsening of intrusion symptoms. The signal was symptom reduction, not provocation.

A 2021 follow-up trial by Feder et al., published in the American Journal of Psychiatry, extended the work to repeated infusions in chronic PTSD. Patients receiving six ketamine infusions over two weeks showed significant and sustained reductions in PTSD symptoms compared to midazolam. Again, dissociation during the infusion did not translate into worsening intrusions afterward.

A 2018 study by Albott and colleagues, published in the Journal of Clinical Psychiatry, looked specifically at veterans with comorbid PTSD and depression. Repeated ketamine infusions reduced both PTSD and depression symptoms without inducing flashbacks or persistent dissociative phenomena. This is meaningful because veterans with combat PTSD are exactly the population where iatrogenic flashbacks would be most concerning, and it did not happen.

Across the published PTSD trials, the consistent finding is that the dissociation experienced during ketamine infusion is acute and time-limited, while the post-treatment trajectory is reduced intrusions, reduced hyperarousal, and improved functioning. — Synthesizing Feder et al., JAMA Psychiatry 2014; Feder et al., AJP 2021; Albott et al., J Clin Psychiatry 2018

Ketamine is FDA-approved as an anesthetic; its use for PTSD is off-label. The body of randomized evidence is still smaller than what exists for depression, but the direction of the data is consistent. We treat PTSD with this in mind—the goal is calming the trauma response, not retraumatizing it. (For a deeper look at protocols and outcomes, see our overview of ketamine for PTSD.)

Risk factors and screening before treatment

Not every patient with a trauma history will have the same experience under ketamine, and we screen for that. A careful intake helps us understand which factors might shape the session:

This is one reason we ask patients to share what they are comfortable sharing in advance. Screening is not gatekeeping. It is how we tailor the experience to be helpful instead of overwhelming. We work with veterans and first responders regularly, and the screening conversation is shaped by that experience.

Set, setting, and dosing — how we keep the experience contained

The phrase set and setting originated in psychedelic research, and it applies here. Set is the patient’s mindset coming in. Setting is the physical and relational environment. Both shape what the medicine does.

For PTSD-sensitive patients, we use lower starting doses than we might for treatment-resistant depression alone. We slow the titration. We ask about music preferences in advance, because an unexpected song can pull a patient toward material they were not ready to meet. The room is private, the recliner is comfortable, and the lighting is low. Marla Peterson, CRNA, oversees every infusion and provides anesthesia-level monitoring throughout, which means continuous pulse oximetry, blood pressure, and heart rate tracking. A clinician is available throughout the session to provide grounding if the patient asks for it.

The contained, predictable structure of a clinical infusion is itself a therapeutic feature for PTSD. It is the opposite of the unpredictable, threatening conditions that gave rise to the trauma in the first place.

What to do if difficult material does surface

Sometimes, even with good screening, traumatic memory or emotional content surfaces during a session. This is not the same as a flashback—most often it is a memory that becomes available with less defensive armor than usual, and it can be sat with rather than fled from.

If that happens, a few principles apply. The clinician stays nearby. The patient is reminded where they are and that the experience is finite. Eye contact, a steady voice, sometimes a hand on the shoulder if welcomed. Patients are told ahead of time that they can ask for the lights to come up, the music to change, or the session to be paused for grounding.

The most important step happens after the infusion: integration. Talking through what came up—with us, with a trauma-informed therapist, or both—is how the material gets metabolized rather than re-stored. PTSD treatment without integration support is incomplete. We coordinate with outside therapists when patients have them, and we can refer when they do not.

HPPD and persistent perceptual effects — the honest answer

Some readers will have heard of Hallucinogen Persisting Perception Disorder (HPPD), a condition where visual disturbances—trails, halos, snow—persist long after a hallucinogen has cleared the body. It is recognized in the DSM-5 and described primarily in the context of classical psychedelics like LSD and, more recently, recreational ketamine misuse.

The literature on HPPD specifically following supervised, therapeutic ketamine at standard sub-anesthetic doses is very limited. The condition appears to be rare in this setting. Most case reports involving ketamine and persistent perceptual changes are tied to high-dose or long-term recreational use, not to the kind of dosing used in clinical practice. We do not minimize the question—HPPD is real and deserves honest disclosure—but the published risk in supervised medical settings is low.

We also want to be clear about what we do not know. The number of long-term studies on therapeutic ketamine in PTSD populations is still smaller than for depression. We use the lowest effective dose, we screen carefully, and we monitor for any persistent perceptual changes at follow-up. If a patient reports them, we take that seriously.

Why a CRNA-led, clinic-based setting matters

Because ketamine is a powerful medication that alters perception, where and how it is administered matters as much as the molecule itself. At Music City Ketamine, every IV infusion is administered by a Certified Registered Nurse Anesthetist—a CRNA—working in a clinical setting with full monitoring. Marla Peterson, CRNA, has decades of anesthesia experience, which is exactly the background you want in the room when working with a dissociative anesthetic in a population sensitive to perceptual changes.

We are transparent about what ketamine cannot do. It does not cure PTSD. It does not replace trauma-focused therapy. It is not a one-time solution and is not appropriate for everyone. It is one tool, and for many patients with treatment-resistant PTSD, research suggests it can rapidly reduce intrusion symptoms, hyperarousal, and the depressive weight that often travels with chronic PTSD. (For more on safety and monitoring across all conditions, see is ketamine therapy safe, and on common misconceptions, ketamine myths.)

Cost is part of an honest conversation, too. Insurance generally does not cover ketamine for PTSD because the use is off-label. At Music City Ketamine, sessions are $475 each, and we walk through the typical course of care during the consultation so you can plan. We also work with veterans on coordination with VA care when appropriate.

The question that brings most patients to this article—can ketamine cause flashbacks?—is a fair, careful question to ask about a treatment that alters perception. The evidence, taken honestly, says: in supervised medical settings with screened patients and appropriate dosing, true flashbacks are rare, and the broader trajectory is symptom reduction. We will keep saying that with the qualifiers it deserves.